American Renal Associates Holdings, Inc. (NYSE:ARA) Q4 2019 Earnings Conference Call - Final Transcript

Mar 16, 2020 • 05:00 pm ET

Previous

American Renal Associates Holdings, Inc. (NYSE:ARA) Q4 2019 Earnings Conference Call - Final Transcript

Share
Close

Loading Event

Loading Transcript

Presentation
Operator
Operator

Greetings, and welcome to the American Renal Associates fourth-quarter 2019 earnings conference call. [Operator instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Darren Lehrich, senior vice president. Please go ahead, sir.

Executive
Darren Lehrich

Thank you, operator. Good afternoon, everyone, and welcome to our fourth-quarter 2019 earnings conference call and webcast. Joining me for today's presentation are Joe Carlucci, our chairman and CEO; Mark Herbers, our interim CFO; and Dr. Don Williamson, our COO.

Also joining on the call today are Syed Kamal, our president; and Jillian Bernard, our controller. I want to remind everyone that we may make certain remarks today that constitute forward-looking statements within the meaning of the federal securities laws. The company's actual results may differ materially from such statements due to a number of risks and uncertainties, including those described in our most recent Form 10-K. Any forward-looking statements made in this call are effective only as of today, and the company undertakes no obligation to revise or update any forward-looking statement for any reason.

On today's call, we will refer to certain non-GAAP financial measures. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available as is important information concerning the use of non-GAAP measures, generally, in the press release and our current Investor Relations presentation deck both of which are available within the Investor Relations section of our website at americanrenal.com. On today's call, we will also be discussing our guidance for 2020. I want to note that our guidance ranges could be impacted by a variety of factors that are discussed in greater detail in the risk factors in our SEC filings, including our most recent 10-K and press release.

I also want to remind you that our adjusted EBITDA, less NCI calculations, do not include the cost of certain legal and other matters, including costs relating to certain litigation and the SEC investigation. With that, I'm pleased to turn the call over to Joe Carlucci.

Joe Carlucci -- Chairman and Chief Executive Officer

Thank you, Darren, and good afternoon, everyone. The coronavirus has proven to be challenging for our entire country and our healthcare system, and I'm humbled by the dedication and hard work of all healthcare workers and especially the efforts of our organization's preparedness for COVID-19. ARA caregivers across 27 states are playing a critical role day-to-day to keep patients and staff healthy and safe during this time. Dr.

Don Williamson will be providing more detailed remarks on this topic in his prepared remarks. But I want to start by saying thank you to our staff, our physician partners for everything they are doing in this rapidly evolving public health crisis. Before I get into the quarter, I want to make a few remarks about my decision to retire as CEO. I have enjoyed a wonderful 42-year career in the healthcare industry.

Cofounding ARA some 20 years ago and leading the growth of this organization for